Showing 5 results for Shatizadeh Malekshahi
Volume 9, Issue 4 (Fall 2023)
Abstract
Aims: The purpose of this study is to evaluate the viral load of active human cytomegalovirus (HCMV) infection in the plasma samples of people suspected of kidney transplant rejection and to investigate the host and risk factors related to the activation of HCMV in these patients.
Materials & Methods: This cross-sectional study was conducted between December 2022 and June 2023. In this study, 98 blood samples related to patients suspected of kidney transplant rejection referring to Labbafinezhad hospital in Tehran were collected. The samples were tested by the GeneProof Cytomegalovirus (CMV) PCR Kit to determine HCMV viral load. ROC curve analysis was used to determine the viral load cutoff point.
Findings: HCMV viremia was detected in 18 (18.36%) of 98 transplant recipients. The median viral load in the HCMV viremia group was 24914.0 IU/ml (5147.0-155106.5). The optimal cut-off value for HCMV was determined 778 IU/ml using ROC analysis. Duration of time after transplantation in the viremia and no viremia groups was 120.5 and 46 months, respectively with a statistically significant difference (P=0.014).
Conclusion: This study provides valuable insights into the prevalence of HCMV viremia and its associated risk factors in kidney transplant recipients suspected of rejection. The study also highlights the importance of post-transplant monitoring and preventive measures to address viral infections. Quick and timely diagnosis of viral activation in kidney transplant patients is effective and mandatory for patient management and the use of appropriate preventive and therapeutic strategies that lead to the reduction of nephropathy, transplant rejection and other diseases. Long-term studies with larger sample sizes are needed to evaluate the role of factors influencing the occurrence of viremia after transplantation.
Volume 11, Issue 2 (Spring 2025)
Abstract
Background: Considering the limited studies conducted on the possibility of vertical transmission of HHV-6 in humans at different stages of pregnancy, the objective of this research wasis to examine the vertical transmission of HHV-6 (human herpesvirus 6) in various tissues of aborted fetuses atduring different months of pregnancy.
Materials & Methods: This research was conducted on used 58 formalin- fixed paraffin- embedded tissues (FFPE) from 26 fetopsies. DNA extraction was performed using the phenol-chloroform technique. The quantity of extracted DNA samples was measured using the NanoDrop spectrophotometric method. PCR of the beta-globin gene confirmed the quality of the extracted DNA, and then the presence of the HHV-6 genome was tested using the Rreal-time PCR method.
Findings: Of the 26 fetuses examined, 22 (84.6%) were negative for HHV-6, and four (15.4%) were positive. All six first-trimester fetuses were negative. Among 13 second-trimester fetuses (29 FFPE tissues), two (7.7%) tested positive., wWhile none of the seven third-trimester fetuses (22 FFPE tissues) had placental positive placentasity. However, HHV-6 was detected in non-placental fetal tissues, including the liver of fetus No. 16 and the heart of fetus No. 22, both of which were in the third trimester.
Conclusion: These findings suggest that while vertical transmission of HHV-6 may occur, particularly in later stages of pregnancy andor in specific fetal tissues, the overall prevalence in theis sample studied was relatively low. Further investigation is needed to understand the implications of these results for maternal and fetal health.
Volume 23, Issue 4 (Fall 2020)
Abstract
Aims: Human herpes virus 6 (HHV-6) is a ubiquitous virus with a high rate of prevalence worldwide. In recent years, a new form of the virus genome has been identified called Chromosomally integrated HHV-6 (ciHHV-6). Further studies are required to elucidate the relation between ciHHV-6 and other clinical complications. The purpose of this study was to summarize the literature on different clinical aspects of the ciHHV-6 integration and its prevalevce in different communities.
Materials and methods: Search keywords include HHV-6, integrated genome, telomeric regions and integrated HHV-6. Scientific databases such as scopus, PubMed and google scholar with no specified start date were used for information collection.
Findings: About 1% of global populations are infected with ciHHV-6. Real-time PCR can be used to differentiate between ciHHV-6 and HHV-6 acute infection in which the viral load will be higher in ciHHV-6 compared to the acute infection. However, ciHHV-6 can be confirmed by evidence of one copy of viral DNA in hair or nail follicles. It has been shown that ciHHV-6 may disrupt the telomer stability.
Conclutions: To date, no treatment has been discovered to remove the viral genome from the host cells. Taken together, the integrated form of the HHV-6 genome could be linked to the various diseases, including heart and autoimmune diseases. But further studies are needed to find its association with other diseases in different geographic area.
Volume 24, Issue 1 (Spring 2021)
Abstract
Respiratory influenza infection is one of the leading causes of global morbidity and mortality, affecting approximately 10% -20% of the world’s population annually. According to recent estimates, about 398,000 deaths per year are associated with influenza respiratory infections with a mortality rate of 2% among viral respiratory infections. During the seasonal and pandemic influenza outbreaks, it has been found that pregnant women are more likely to have severe influenza-related complications, compared to the general population. During pregnancy, immunological and physiological changes that affect the respiratory system, cardiovascular system, and other systems put women at greater risk for certain infections and related complications. In this review study, we first briefly discuss the characteristics of influenza virus infection and its epidemiology, and then discuss the clinical aspects of influenza virus infection in pregnant women and fetuses.
Volume 26, Issue 3 (Summer 2023)
Abstract
Kidney transplantation is one of the best treatment methods for people with chronic kidney failure, and a large number of kidney transplants are performed worldwide every year. Pathogens that commonly infect kidney transplant recipients are viruses, bacteria, and protozoa. Among these, viruses are considered one of the biggest life-threatening factors in kidney transplant recipients. The reactivation of herpesviruses from the latent state often occurs in conditions of weakening the immune system, including after kidney transplantation. Infection with herpesviruses is still one of the main causes of complications and death for most kidney transplant recipients. Rapid diagnosis of active infection of these viruses in kidney transplant patients has a significant impact on the use of appropriate treatment strategies to reduce complications and transplant rejection. For this reason, this review aims to provide information about the preventive strategies, diagnosis, and treatment of herpesviruses infections in kidney transplant recipients. In this brief review, we have updated the information presented in previous articles and adjusted it based on recent advances, updated clinical guidelines, and common post-transplant tactics to minimize the risk of infection.
